Abstract: Immune checkpoint inhibitors (ICIs) have emerged as one of the novel immunotherapy drugs in recent years, and been approved for the treatment of multiple tumour types. However, over-activation of the immune system may lead to immune-related advese events, among these, ICIs-induced cardiotoxicity include myocarditis, pericardial disease, atherosclerosis and vasculitis. Although ICIs-induced cardiotoxicity is rare, it may lead to serious clinical complications and even death. Thus, timely identification and management of ICIs-induced cardiotoxicity is vital in clinical practice. Once diagnosed, prompt treatment is required according to the severity of the disease. Standardized prevention and treatment strategies need multidisciplinary collaboration to provide long-term individualized monitoring and management for patients.